Funds and ETFs Compugen Ltd.

Equities

CGEN

IL0010852080

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-26 pm EDT 5-day change 1st Jan Change
1.92 USD +1.05% Intraday chart for Compugen Ltd. +1.05% -3.03%

ETFs positioned on Compugen Ltd.

Name Weight AuM 1st Jan change Investor Rating
0.01% 0 M€ 0.00% -
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.92 USD
Average target price
5.333 USD
Spread / Average Target
+177.78%
Consensus
  1. Stock Market
  2. Equities
  3. CGEN Stock
  4. Funds and ETFs Compugen Ltd.